The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network

OBJECTIVE: The management of prediabetes and hyperglycemia is an increasingly important aspect of care in patients with thalassemia. In light of the limited evidence about the management of GD (glucose dysregulation) with glucose-lowering agents (GLAs), we have conducted a retrospective survey in TD...

Descripción completa

Detalles Bibliográficos
Autores principales: de Sanctis, Vincenzo, Soliman, Ashraf, Tzoulis, Ploutarchos, Daar, Shahina, Kattamis, Antonis, Delaporta, Polyxeni, Karimi, Mehran, Yassin, Mohamed A., Zarei, Tahereh, Saki, Forough, Sapunarova, Katia, Banchev, Atanas, Galati, Maria Concetta, Raiola, Giuseppe, Messina, Giuseppe, Campisi, Saveria, Kattamis, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171892/
https://www.ncbi.nlm.nih.gov/pubmed/35546014
http://dx.doi.org/10.23750/abm.v93i2.12056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171892/
https://www.ncbi.nlm.nih.gov/pubmed/35546014
http://dx.doi.org/10.23750/abm.v93i2.12056

Ejemplares similares